

# SUSAN M FREEMAN MD

---



Susan M Freeman, MD  
2131 S Lafayette St  
Denver, CO 80210  
[smfreeman@me.com](mailto:smfreeman@me.com)  
Cell: 303-898-9351

## PROFILE

I am an award winning medical oncologist with over 30 years of clinical experience. I am recently retired from full time medical practice with the Colorado Permanente Medical Group (CPMG) after nearly 17 years of service. I will be starting part time work as a medical oncologist at Pagosa Springs Medical Center in January 2026. I established Shoshanna Medical Consulting, LLC fall of 2025 for medical consulting, expert work in and locum tenens for clinical practice. I have experience in departmental and program leadership, quality improvement and medical education.

## EXPERIENCE

**Part time medical oncologist, starting January 2026 at Pagosa Springs Medical Center.**

**Shoshanna Medical Consulting, LLC, established 9/2025.**

Locum tenens part time medical oncologist, consultation on cancer center program development/organization, non management second opinion consultation for breast cancer, medical oncology expert.

**Colorado Permanente Medical Group (CPMG, physician part of Kaiser Permanente Colorado (KPCO), 10/8/2008-6/30/2025.**

For the past nearly 17 years, I have practiced KPCO as a full time medical oncologist. My career has been focused on the treatment of women's cancers; however, I have treated the majority of all solid tumors. I've been involved in leadership: I was the chief of our oncology department and head of our multidisciplinary breast cancer program.

**Rocky Mountain Cancer Centers, 1994-2008**

Full time practice of medical oncology with a focus on breast cancer and gynecologic cancers. Founded/implemented multidisciplinary breast program.

**Colorado Breast Specialists, 1993-1994**

My first position after fellowship training with one other oncologist in a breast cancer specialty practice.

## **Clinical Instructor and specialty fellowship in autologous bone marrow transplantation at UCH (University of Colorado Hospitals) — 1992-1993**

### **EDUCATION/TRAINING**

1983 BA with honors in government from University of Texas (Austin), started at Northwestern University in 1979 , transferred to UT as a junior

1987 MD from Baylor College of Medicine (BCOM)

1990 Completed internal medicine residency at The University of Chicago Hospital

1992 Completed hematology/oncology fellowship at The University of Chicago Hospital

1993 Completed autologous bone marrow transplant fellowship at The University of Colorado Health Sciences Center (UCH). This fellowship included bench lab research in megakaryocytes in the lab of Dr. EJ Shpall

### **BOARD CERTIFICATION**

ABIM (American Board of Internal Medicine, #131651)

Internal Medicine: initial 1990, recertification, 2000, now inactive due to sole practice of medical oncology

Medical Oncology: initial 1993, re certified 2003, 2013, 2023 (good thru 2033), enrolled in MOC (maintenance of certification) program

### **SKILLS**

Experienced on EPIC and Meditech EMR, including Beacon chemotherapy ordering module, cancer staging/oncology history features, and clinical pathways utilization.

Chemotherapy ordering and side effect management.

Cancer program development, implementation, oversight and monitoring.

Participation in clinical trials.

Skilled lecturer and educator. Involved in oncology teaching for residents at St. Joseph's hospital (Denver, CO) from 2008 thru 2023. Did both formal lectures as well as teaching on oncology rounds and at the bedside.

BLS certified via EDCOR current through 1/2026

## **LEADERSHIP**

Member and chairman, Cancer Committee of The Medical Center of Aurora, 1993-2008

Speaker's Bureau for Myriad Genetics Lab

Member of CPMG physician wellness committee (a board subcommittee) 2012-2014

Department value advisor (quality) for CPMG medical oncology 2015-2016

Medical oncology team leader for KCPO breast cancer program 2010-2015

Area Specialty Chief of Medical Oncology (Colorado Permanente Medical Group), 2015-2018

Breast Cancer Program leader (entire multidisciplinary group) 2016-2019

## **AWARDS**

Phi Lambda Delta, Northwestern University, 1980

Phi Beta Kappa, University of Texas, 1983

Outstanding student in clinical neurology BCOM, 1986

Resident Teaching Award, Pritzker School of Medicine, 1987 x 2, and 1988 x 2

Alpha Omega Alpha (AOA), from Pritzker School of Medicine, 1989

Community Outreach Award from Rocky Mountain Cancer Centers (RMCC), 2005

Vohs Award from KPCO for best new program- multidisciplinary breast clinics

Award for top 100 doctors of CPMG (out of >1000 physicians) based on patient satisfaction scores, 2019

5280 Magazine's Denver Top Doctor 2021.

## **CITIZENSHIP**

USA

## **MEDICAL LICENSURE**

State Board of Illinois: (12/08/88-06/30/93), #003036078208, chose not to renew due to moving out of state for additional fellowship training.

State Board of Colorado: 05/08/92- present (current licensure is thru 4/30/2027), #31746

Federal DEA: 01/89-present, #BF1685835

National provider ID (NPI): 1861476400

Medicare provider ID: CO301799

BLS certification up to date thru 1/2026 and will remain up to date

## RESEARCH/PUBLICATIONS

### PUBLICATIONS

1. Geller, RB, **Myers SE**, Devine S, Larson, RA, Williams S, Park CL, O'Toole K, Chandler C: A Phase I study of Busulfan, Cyclophosphamide and Time Sequential Escalation Doses of Cytarabine followed by Bone Marrow Transplantation. *Bone Marrow Transplantation* 9:41-47, 1992.
2. **Myers SE** and Schilsky RL: Prospects of Fertility after Chemotherapy. *Seminars in Oncology* 19(5): 597-604.
3. **Myers, SE**, Williams SF, Geller RB: Cyclophosphamide Mobilization of Peripheral Blood Stem Cells for Use in Autologous Transplantation After High-Dose Chemotherapy: Clinical Results in Patients with Contaminated or Hypocellular Bone Marrow. *J Hematotherapy* 1:27-33, 1992.
4. Bender JG, Williams SF, **Myers SE**, Nottelman D Lee WJ, Unversaft KL, Walter D, VanEpps D: Characterization of Chemotherapy Mobilized Peripheral Blood Progenitor Cells for Use in Autologous Transplantation. *Bone Marrow Transplantation* 10:281-285, 1992.
5. **Myers SE**, Devine SM, Topper RL, Ondrey M, O'Toole K, Chandler C, Williams SF, Larson RA, Geller RB: A Pilot Study of Aerosolized Amphotericin B in Patients at Risk for prolonged neutropenia. *Leukemia and Lymphoma* 8:229-233, 1992.
6. **Myers SE** and Williams SF: The Role of High-Dose Chemotherapy and Autologous Stem Cell Support in the Treatment of Breast Cancer. *Heme/Onc Clinics of North America* 7(3): 631-645, 1993.
7. Jones RB, Matthes S, Dutton C, Bearman SI, Stemmer SM, **Myers SE**, Shpall EJ: Pharmacokinetic/pharmacodynamic interactions of intensive cyclophosphamide, cisplatin and BCNU in patients with breast cancer. *Breast Cancer Research and Treatment* 26: 11-17, 1993.
8. Shpall EJ, Jones RB, Bearman SI, Franklin WA, Archer PA, Curiel T, Bitter M, Claman HN, Stemmer SM, Purdy MA, **Myers SE**, Hami L, Taffs S, Hemfeld S, Hallagan J, Berenson R: Transplantation of CD34 positive Autologous Bone Marrow into Breast Cancer Patients Following High Dose Chemotherapy: Influence of CD34+ positive Peripheral Blood Progenitors

8. and Growth Factor Engraftment. *Journal of Clinical Oncology* 12(1); 36-38, 1994.

#### ABSTRACTS

1. **Myers SE**, Taffett G, Teasdale T, Orso F, Luchi R: Failure of lymphopenia to predict outcome in elderly infected patients. *Gerontologist* 26:184a (206), 1985.
2. **Myers SE**, Williams SF, Geller RB, Joyce L, Barker S: Cyclophosphamide mobilization of peripheral blood stem cells for use in autologous transplantation after high-dose chemotherapy. *Int J Cell Cloning* 10P:192, 1992 and *Blood* 78(1): supplement 1, 505a, 1991
3. **Myers SE**, Devine SM, Topper RL, Ondrey M, Ramming K, Chandler C, Williams SF, Larson RA, Geller R: A Phase I trial of prophylactic aerosolized Amphotericin B in patients at risk for prolonged neutropenia. *Blood* 78 (10): supplement 1, 234a, 1991.
4. Shpall EJ, Jones RB, Franklin W, Bearman S, Stemmer S, **Myers SE**, Purdy M, Hami L, Heimfeld S, Berenson R: Transplantation of enriched autologous peripheral blood progenitor cells into breast cancer patients following high-dose chemotherapy. Presented at the *International Symposium on Peripheral Blood Autografts, Bordeaux, France, October 1993*.
5. Zimmerman, T, Mick R, **Myers SE**, Bender J, and Williams S: Source of stem cell progenitors impacts upon hematopoietic recovery after high-dose chemotherapy, *Proceedings ASCO* 12:89a, 72, 1992.
6. Stemmer SM, Shpall EJ, Jones RB, Hami L, Bearman SI, **Myers SE**, Taff S, Shaw L, Capizzi RL, Schein P: Amifostene (WR-27210) shortens the engraftment time of 4-hydroxyperoxy-cyclophosphamide (4HC) purged bone marrow in lymphoma patients receiving high dose chemotherapy with autologous bone marrow support, *Blood* 80(10): supplement 1, 269, 70a, 1992.
7. Stemmer SM, Jones RB, Bearman SI, Purdy M, **Myers SE**, Shpall EJ: Intensive Taxol/cyclophosphamide/cisplatin (Taxol/CPA/CDDP) with autologous hematopoietic support. *Proceedings ASCO* 1994.
8. Bearman SI, Jones RB, Shpall EJ, Stemmer SM, **Myers SE**, Purdy: High dose chemotherapy with autologous progenitor cell support for Stage IV NED breast cancer. *Proceeding ASCO*, 1994.

9. Williams SF, **Myers SE**, Huffman S, Mick R, Bitran J: Mitoxantrone, vincristine, and 5-fluorouracil with leucovorin modulation as induction chemotherapy prior to high-dose intensification in metastatic breast cancer , *Breast Cancer Research and Treatment* 28:291-294, 1993.
10. **Myers SE**, Mick R, and Williams SF: High dose chemotherapy with autologous stem cell rescue in women with metastatic breast cancer with involved bone marrow: A role for peripheral blood progenitor transplants. *Bone Marrow Transplantation* 13:341-344, 1994.
11. **Myers SE** and Williams SF: Guillan-Barre syndrome after autologous bone marrow transplantation for metastatic breast cancer: A report of two cases. *Bone Marrow Transplantation* 13:341-344, 1994.

#### REFERENCES/HOSPITAL AFFILIATIONS UPON REQUEST

*Susan M Freeman, MD*

Updated 9/30/2025